Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

Venkat Nelabhotla, CEO of Vyome

“We believe this Notice of Allowance significantly strengthens the intellectual property foundation around VT-1908. While uveitis is our initial development focus, our longer-term vision is much broader. Topical steroids are extensively used across ocular inflammatory conditions, and there remains a significant need for effective steroid-sparing alternatives. We believe VT-1908 has the potential to address this broader need across an ocular inflammation market opportunity exceeding $20 billion. With strong intellectual property and peer-reviewed scientific validation, we believe VT-1908 represents an important additional value driver within Vyome’s immuno-inflammatory pipeline.”

Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and Co-Founder of Vyome

“Mycophenolate is a well-established immunomodulator, but delivering it effectively as a topical ophthalmic therapy required solving significant formulation and drug-delivery challenges. Our published preclinical work demonstrated that topical VT-1908 can potentially achieve the desired ocular exposure and produce anti-inflammatory efficacy comparable to a steroid in the uveitis model. The USPTO Notice of Allowance further validates the novelty of the formulation and methods underlying this approach and supports our broader scientific objective of developing a non-steroidal alternative for inflammatory diseases of the eye.”